Wegovy's mechanism of action: what semaglutide actually does in the body

The biggest myth: Wegovy works by making you feel sick

This one comes up often, and it is worth addressing head-on. Some people do experience nausea in the early weeks of treatment (particularly around the time of starting or moving to a higher dose) and it is easy to see why an outsider might conclude that weight loss happens because food becomes unpleasant. That is not the mechanism. The nausea is a side effect of the dose titration period, not the therapeutic intent. What Wegovy is actually doing is something more fundamental: it is altering the signals your brain receives about hunger, satiety and food reward.

GLP-1 is released naturally from cells lining your gut when you eat. It travels to the brain's hypothalamus, where it tells you that you have had enough. It also signals to the stomach to slow down how quickly food moves through it, which extends the physical sensation of fullness. Semaglutide binds to the same receptors that natural GLP-1 uses, but because it is a modified molecule, it stays active far longer, long enough for a once-weekly injection to maintain a sustained effect. The goal is not to make eating uncomfortable; it is to restore a hormonal signal that, in many people with obesity, has become blunted. The NHS medicines page on semaglutide sets this out clearly in patient-facing terms.

Nausea, when it does occur, is most common in the first few weeks and tends to settle. It is a reason to adjust the titration schedule if needed, not a sign that the medicine is working correctly by making meals unpleasant.

What GLP-1 receptor agonism actually means, without the jargon

Your digestive system produces several hormones after a meal. GLP-1 (glucagon-like peptide-1) is one of them. Its job, broadly, is to coordinate the body's response to incoming food: signal fullness to the brain, slow the stomach, encourage appropriate insulin release and suppress glucagon (a hormone that raises blood sugar). In people with obesity, this system can underperform; the satiety signal arrives late or at lower intensity, making it harder to stop eating at the point where the body has genuinely had enough.

Semaglutide is a structural analogue of GLP-1. It is close enough to the natural hormone to fit the same receptor, but different enough that enzymes in the body cannot break it down quickly. That stability is what gives it its once-weekly pharmacokinetic profile. When the receptor is activated, the downstream effects are the same as with natural GLP-1, just sustained over days rather than minutes.

The practical outcome for most people is a reduced appetite, smaller portion sizes feeling satisfying, and less preoccupation with food between meals. These are not psychological tricks; they reflect measurable changes in hormonal signalling. For a broader look at how semaglutide fits into the weight-loss medicine landscape, the semaglutide overview on this site gives helpful context. If you are curious about how a dual-pathway medicine compares, the semaglutide mechanism of action page explores the difference between GLP-1-only and dual GIP/GLP-1 activation in more depth.

The STEP 1 trial: what the evidence showed

The pivotal clinical evidence for Wegovy at the 2.4mg weekly dose comes from the STEP programme, particularly STEP 1, a 68-week randomised controlled trial in adults with obesity or overweight plus a weight-related condition, without type 2 diabetes. Participants on semaglutide 2.4mg achieved an average body-weight reduction of around 15%, compared with approximately 2.4% in the placebo group. That is a meaningful difference, and it was achieved alongside lifestyle support (a reduced-calorie diet and increased physical activity) not as a standalone intervention. The trial was published in the New England Journal of Medicine and remains the most frequently cited piece of evidence for semaglutide's efficacy in weight management.

Results varied across participants, and clinical trials measure averages across large populations. Some people lose more, some less, and the medicine works best as part of a structured approach. There is also now a higher-dose option, and you can read more about what that involves on the Wegovy 2 page, which covers the 7.2mg dose approved by the MHRA in April 2026 for adults with a BMI of 30 or above, with trial data reporting around 20.7% average weight loss over 72 weeks at that dose. Whether that option is appropriate for any individual is a question for their prescriber. You can read more about the Wegovy treatment overview, including the dose pathway, on this site.

Understanding the mechanism helps put the numbers in context. The weight loss in these trials is not from reduced calorie absorption or increased metabolism in isolation; it is primarily from a sustained reduction in energy intake, driven by changed appetite signalling. That is also why what you eat during treatment (adequate protein, fibre, hydration) matters. The medicine changes the signal; the behaviour still shapes the outcome. For information on how treatment costs fit into the picture, the Wegovy price and cost guide covers what a private prescription typically involves in the UK. The weight-loss treatment overview gives a broader picture of the options available through nume.

How this applies when you are deciding whether to pursue treatment

Understanding the mechanism matters for one practical reason: it helps set realistic expectations. Wegovy is not suppressing your appetite by force of will; it is working with a hormonal pathway your body already has. That means it tends to feel less like restriction and more like a reduction in preoccupation with food, though experiences differ. It also means that stopping treatment typically reverses those hormonal effects over time, which is why ongoing clinical support matters. The nume FAQs cover common questions about what happens with repeat prescriptions and clinical reviews.

As a prescription-only medicine, Wegovy requires clinical assessment before it can be prescribed. The prescriber considers your BMI, weight-related health conditions, medical history and current medicines, including things like contraception, since starting Wegovy at lower doses involves a careful titration period. The eligibility thresholds under the private licence are a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally. That clinical review happens the same day. If you are ready to understand whether this medicine could be appropriate for you, speaking to our prescribers is the straightforward next step.